62 related articles for article (PubMed ID: 33852454)
1. Validation of Tools for Predicting Incident Adenocarcinoma of the Esophagus or Esophagogastric Junction.
Rubenstein JH; Raghunathan T; Doan C; Schneider J; Zhao W; Metko V; Nofz K; Khodadost M; Corley DA
Am J Gastroenterol; 2021 May; 116(5):949-957. PubMed ID: 33852454
[TBL] [Abstract][Full Text] [Related]
2. Predicting Incident Adenocarcinoma of the Esophagus or Gastric Cardia Using Machine Learning of Electronic Health Records.
Rubenstein JH; Fontaine S; MacDonald PW; Burns JA; Evans RR; Arasim ME; Chang JW; Firsht EM; Hawley ST; Saini SD; Wallner LP; Zhu J; Waljee AK
Gastroenterology; 2023 Dec; 165(6):1420-1429.e10. PubMed ID: 37597631
[TBL] [Abstract][Full Text] [Related]
3. Patients With Esophageal Adenocarcinoma With Prior Gastroesophageal Reflux Disease Symptoms Are Similar to Those Without Gastroesophageal Reflux Disease: A Cross-Sectional Study.
Chandar AK; Keerthy K; Gupta R; Grady WM; Canto MI; Shaheen NJ; Thota PN; Iyer PG; Wang JS; Falk GW; Abrams JA; Dumot J; Faulx A; Markowitz SD; Willis J; Moinova H; Guda K; Brock W; Chak A
Am J Gastroenterol; 2024 May; 119(5):823-829. PubMed ID: 37975600
[TBL] [Abstract][Full Text] [Related]
4. Population Based Time Trends in the Epidemiology and Mortality of Gastroesophageal Junction and Esophageal Adenocarcinoma.
Agarwal S; Bell MG; Dhaliwal L; Codipilly DC; Dierkhising RA; Lansing R; Gibbons EE; Leggett CL; Kisiel JB; Iyer PG
Dig Dis Sci; 2024 Jan; 69(1):246-253. PubMed ID: 37914889
[TBL] [Abstract][Full Text] [Related]
5. Esophageal adenocarcinoma incidence in individuals with gastroesophageal reflux: synthesis and estimates from population studies.
Rubenstein JH; Scheiman JM; Sadeghi S; Whiteman D; Inadomi JM
Am J Gastroenterol; 2011 Feb; 106(2):254-60. PubMed ID: 21139576
[TBL] [Abstract][Full Text] [Related]
6. A functional epidermal growth factor (EGF) polymorphism, EGF serum levels, and esophageal adenocarcinoma risk and outcome.
Lanuti M; Liu G; Goodwin JM; Zhai R; Fuchs BC; Asomaning K; Su L; Nishioka NS; Tanabe KK; Christiani DC
Clin Cancer Res; 2008 May; 14(10):3216-22. PubMed ID: 18483390
[TBL] [Abstract][Full Text] [Related]
7. Development of Electronic Health Record-Based Machine Learning Models to Predict Barrett's Esophagus and Esophageal Adenocarcinoma Risk.
Iyer PG; Sachdeva K; Leggett CL; Codipilly DC; Abbas H; Anderson K; Kisiel JB; Asfahan S; Awasthi S; Anand P; Kumar M P; Singh SP; Shukla S; Bade S; Mahto C; Singh N; Yadav S; Padhye C
Clin Transl Gastroenterol; 2023 Oct; 14(10):e00637. PubMed ID: 37698203
[TBL] [Abstract][Full Text] [Related]
8. Esophageal adenocarcinoma heterogeneity in clinicopathology and prognosis: A single center longitudinal study of 146 cases over a 20-year period.
Huang Q; Lew E; Cheng Y; Shinagare S; Deshpande V; Gold JS; Wiener D; Weber HC
Ann Diagn Pathol; 2024 Jun; 70():152285. PubMed ID: 38518703
[TBL] [Abstract][Full Text] [Related]
9. Low Prevalence of Endoscopic Screening for Barrett's Esophagus in a Screening-Eligible Primary Care Population.
Eluri S; Reddy S; Ketchem CC; Tappata M; Nettles HG; Watts AE; Cotton CC; Dellon ES; Shaheen NJ
Am J Gastroenterol; 2022 Nov; 117(11):1764-1771. PubMed ID: 35971219
[TBL] [Abstract][Full Text] [Related]
10. Patient Knowledge, Risk Perception, and Barriers to Barrett's Esophagus Screening.
Kolb JM; Chen M; Tavakkoli A; Gallegos J; O'Hara J; Tarter W; Hochheimer CJ; Golubski B; Kopplin N; Hennessey L; Kalluri A; Devireddy S; Scott FI; Falk GW; Singal AG; Vajravelu RK; Wani S
Am J Gastroenterol; 2023 Apr; 118(4):615-626. PubMed ID: 36219171
[TBL] [Abstract][Full Text] [Related]
11. Dating the rise of esophageal adenocarcinoma: analysis of Connecticut Tumor Registry data, 1940-2007.
Abrams JA; Sharaiha RZ; Gonsalves L; Lightdale CJ; Neugut AI
Cancer Epidemiol Biomarkers Prev; 2011 Jan; 20(1):183-6. PubMed ID: 21127287
[TBL] [Abstract][Full Text] [Related]
12. Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the International BEACON Consortium.
Hoyo C; Cook MB; Kamangar F; Freedman ND; Whiteman DC; Bernstein L; Brown LM; Risch HA; Ye W; Sharp L; Wu AH; Ward MH; Casson AG; Murray LJ; Corley DA; Nyrén O; Pandeya N; Vaughan TL; Chow WH; Gammon MD
Int J Epidemiol; 2012 Dec; 41(6):1706-18. PubMed ID: 23148106
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease.
Buas MF; Vaughan TL
Semin Radiat Oncol; 2013 Jan; 23(1):3-9. PubMed ID: 23207041
[TBL] [Abstract][Full Text] [Related]
14. Exploring the recent trend in esophageal adenocarcinoma incidence and mortality using comparative simulation modeling.
Kong CY; Kroep S; Curtius K; Hazelton WD; Jeon J; Meza R; Heberle CR; Miller MC; Choi SE; Lansdorp-Vogelaar I; van Ballegooijen M; Feuer EJ; Inadomi JM; Hur C; Luebeck EG
Cancer Epidemiol Biomarkers Prev; 2014 Jun; 23(6):997-1006. PubMed ID: 24692500
[TBL] [Abstract][Full Text] [Related]
15. Endoscopic Surveillance of Intestinal Metaplasia of the Esophagogastric Junction: A Decision Modeling Analysis.
Yoon JY; Lim F; Shah SC; Rubenstein JH; Abrams JA; Katzka D; Inadomi J; Kim MK; Hur C
Am J Gastroenterol; 2024 Mar; ():. PubMed ID: 38275234
[TBL] [Abstract][Full Text] [Related]
16. The Public's Intended Uptake of Hypothetical Esophageal Adenocarcinoma Screening Scenarios: A Nationwide Survey.
Sijben J; Rainey L; Maas F; Broeders MJM; Siersema PD; Peters Y
Am J Gastroenterol; 2024 May; ():. PubMed ID: 38619114
[TBL] [Abstract][Full Text] [Related]
17. Correlation of Probe-Based Confocal Laser Endomicroscopy (pCLE) and Mucosal Integrity Testing (MIT) with Epithelial Barrier Function and Presence of Gastroesophageal Reflux Disease (GERD).
Mutha PR; Fasullo M; Chu S; Schubert ML; Zfass A; Cooper P; Gill M; Kang L; Vaezi M; Wildhorn S; Slaughter C; Shah T
Dig Dis Sci; 2022 May; 67(5):1773-1782. PubMed ID: 33939145
[TBL] [Abstract][Full Text] [Related]
18. Reflux Esophagitis and Fatigue: Are They Related?
Kang SG; Hwang HJ; Kim Y; Lee J; Oh JH; Kim J; Lim CH; Youn SB; Jung SH
J Clin Med; 2021 Apr; 10(8):. PubMed ID: 33918665
[TBL] [Abstract][Full Text] [Related]
19. Activation of NRF2 by APE1/REF1 is redox-dependent in Barrett's related esophageal adenocarcinoma cells.
Sriramajayam K; Peng D; Lu H; Zhou S; Bhat N; McDonald OG; Que J; Zaika A; El-Rifai W
Redox Biol; 2021 Jul; 43():101970. PubMed ID: 33887608
[TBL] [Abstract][Full Text] [Related]
20. Surveillance Cessation for Barrett's Esophagus: A Survey of Gastroenterologists.
Ozanne EM; Silver ER; Saini SD; Rubenstein JH; Lansdorp-Vogelaar I; Bowers N; Tan SX; Inadomi JM; Hur C
Am J Gastroenterol; 2021 Aug; 116(8):1730-1733. PubMed ID: 34049319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
